Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977348 | 0.89 | BACE1 (0.56) | BACE1BACE2 | |
| SCHEMBL1977346 | 0.89 | BACE1 (0.56) | BACE1BACE2 | |
| Hydrochloric Acid SCHEMBL13268453 | 0.88 | BACE1 (0.55) | BACE1BACE2 | |
| SCHEMBL15800202 | 0.88 | BACE1 (0.58) | BACE1BACE2 | |
| SCHEMBL1978523 | 0.85 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL1976846 | 0.85 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL12981993 | 0.83 | BACE1 (0.53) | BACE1BACE2 | |
| Formic Acid SCHEMBL14732153 | 0.82 | BACE1 (0.56) | BACE1BACE2 | |
| SCHEMBL12980910 | 0.82 | BACE1 (0.61) | BACE1BACE2 | |
| SCHEMBL12981298 | 0.82 | BACE2 (0.56) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | claimed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | claimed |
| US-20140243325-A1 | 1,3-Oxazines as Bace1 and/or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | claimed |
| US-8754075-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-06-17 | — | — | US | claimed |
| EP-2697208-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2014-02-19 | — | — | EP | claimed |
| WO-2012139993-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-18 | — | — | WO | claimed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | claimed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | disclosed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012139993-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-18 | — | — | WO | disclosed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243325-A1 | 1,3-Oxazines as Bace1 and/or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | BACE1 2/4885BACE2 1/4885 |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | BACE1 2/4885BACE2 1/4885 |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | BACE1 2/4885BACE2 1/4885 |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | BACE1 2/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.